TScan Therapeutics Statistics
Share Statistics
TScan Therapeutics has 53.37M shares outstanding. The number of shares has increased by 22.39% in one year.
| Shares Outstanding | 53.37M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.75% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 47.30M |
| Failed to Deliver (FTD) Shares | 8.42K |
| FTD / Avg. Volume | 2.05% |
Short Selling Information
The latest short interest is 2.35M, so 4.4% of the outstanding shares have been sold short.
| Short Interest | 2.35M |
| Short % of Shares Out | 4.4% |
| Short % of Float | 4.96% |
| Short Ratio (days to cover) | 5.8 |
Valuation Ratios
The PE ratio is -4.29 and the forward PE ratio is -4.19.
| PE Ratio | -4.29 |
| Forward PE | -4.19 |
| PS Ratio | 18.17 |
| Forward PS | 11.7 |
| PB Ratio | 2.53 |
| P/FCF Ratio | -5.93 |
| PEG Ratio | n/a |
Enterprise Valuation
TScan Therapeutics Inc. has an Enterprise Value (EV) of 474.88M.
| EV / Earnings | -5.32 |
| EV / Sales | 22.56 |
| EV / EBITDA | -5.93 |
| EV / EBIT | -5.08 |
| EV / FCF | -7.36 |
Financial Position
The company has a current ratio of 6.51, with a Debt / Equity ratio of 0.2.
| Current Ratio | 6.51 |
| Quick Ratio | 6.51 |
| Debt / Equity | 0.2 |
| Total Debt / Capitalization | 16.61 |
| Cash Flow / Debt | -2.04 |
| Interest Coverage | -24.86 |
Financial Efficiency
Return on equity (ROE) is -0.59% and return on capital (ROIC) is -38.41%.
| Return on Equity (ROE) | -0.59% |
| Return on Assets (ROA) | -0.33% |
| Return on Capital (ROIC) | -38.41% |
| Revenue Per Employee | 111.96K |
| Profits Per Employee | -474.56K |
| Employee Count | 188 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -54.91% in the last 52 weeks. The beta is 0.78, so TScan Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.78 |
| 52-Week Price Change | -54.91% |
| 50-Day Moving Average | 3.95 |
| 200-Day Moving Average | 6.02 |
| Relative Strength Index (RSI) | 29.01 |
| Average Volume (20 Days) | 411.02K |
Income Statement
In the last 12 months, TScan Therapeutics had revenue of 21.05M and earned -89.22M in profits. Earnings per share was -1.36.
| Revenue | 21.05M |
| Gross Profit | -67.10M |
| Operating Income | -93.46M |
| Net Income | -89.22M |
| EBITDA | -80.10M |
| EBIT | -93.46M |
| Earnings Per Share (EPS) | -1.36 |
Balance Sheet
The company has 133.36M in cash and 92.43M in debt, giving a net cash position of 40.93M.
| Cash & Cash Equivalents | 133.36M |
| Total Debt | 92.43M |
| Net Cash | 40.93M |
| Retained Earnings | -247.60M |
| Total Assets | 348.03M |
| Working Capital | 245.43M |
Cash Flow
In the last 12 months, operating cash flow was -61.36M and capital expenditures -3.15M, giving a free cash flow of -64.50M.
| Operating Cash Flow | -61.36M |
| Capital Expenditures | -3.15M |
| Free Cash Flow | -64.50M |
| FCF Per Share | -0.98 |
Margins
Gross margin is -318.8%, with operating and profit margins of -444% and -423.86%.
| Gross Margin | -318.8% |
| Operating Margin | -444% |
| Pretax Margin | -423.86% |
| Profit Margin | -423.86% |
| EBITDA Margin | -380.53% |
| EBIT Margin | -444% |
| FCF Margin | -306.45% |
Dividends & Yields
TCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -51.91% |
| FCF Yield | -46.04% |
Analyst Forecast
The average price target for TCRX is $11, which is 319.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 319.8% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -0.71 |
| Piotroski F-Score | 3 |